Givaudan

Last updated January 31, 2026

Innovation Areas

723

Inventors

Collaborations

Trpm8 receptor agonist chemistry: GivaudanRecent Research Landscape

Sensory discomfort or lack of cooling efficacy in topical formulations limits consumer acceptance. These compounds engineer specific molecular interactions with the TRPM8 receptor to provide controlled thermal sensation.

What technical problems is Givaudan addressing in Trpm8 receptor agonist chemistry?

Insufficient sensory cooling efficacy

(4)evidences

Insufficient binding strength and selectivity at the TRPM8 receptor site limits therapeutic efficacy. Improving molecular interaction with the receptor enables precise modulation of cold-sensing pathways.

Insufficient sensory cooling duration

(1)evidences

Transient cooling effects limit the efficacy of topical and oral formulations. Sustained thermal sensation improves consumer satisfaction and therapeutic performance.